Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
National Cancer Institute (NCI)
BeOne Medicines
BeOne Medicines
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre hospitalier de l'Université de Montréal (CHUM)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Dong-A ST Co., Ltd.
Continuity Biosciences, LLC
National Cancer Institute (NCI)
Boehringer Ingelheim
Washington University School of Medicine
University of Southern California
Boehringer Ingelheim
West China Hospital
Medical College of Wisconsin
Incyte Corporation
National Cancer Institute (NCI)
Shanghai Henlius Biotech
Hoffmann-La Roche
Compass Therapeutics
Centre Oscar Lambret
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Seagen Inc.
Seagen Inc.
Eli Lilly and Company
Janssen Research & Development, LLC
Pfizer
Astellas Pharma Inc
Janssen Research & Development, LLC
Novartis